Purcell & Lefkowitz Investigates Zenas BioPharma's Board Actions for Shareholder Breach
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: PRnewswire
- Investigation Launched: Purcell & Lefkowitz LLP is investigating Zenas BioPharma, Inc. to determine if its board breached fiduciary duties in recent corporate actions, which could impact shareholder rights.
- Shareholder Rights Protection: The investigation focuses on safeguarding the interests of Zenas BioPharma shareholders, ensuring they are informed of their rights and options, reflecting a strong emphasis on corporate governance.
- Legal Support Offered: The firm commits to providing affected shareholders with free legal consultations to help them understand the case and take necessary legal actions, enhancing shareholder trust in corporate management.
- Governance Risk Exposure: This investigation highlights potential governance risks at Zenas BioPharma, which may negatively affect shareholder confidence and market performance.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ZBIO with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ZBIO
Wall Street analysts forecast ZBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBIO is 41.20 USD with a low forecast of 19.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.470
Low
19.00
Averages
41.20
High
55.00
Current: 21.470
Low
19.00
Averages
41.20
High
55.00
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz Investigates Zenas BioPharma After 51.86% Stock Drop
- Stock Price Plunge: Zenas BioPharma's stock dropped $17.89, or 51.86%, to close at $16.61 on January 5, 2026, following the announcement of its IgG4-RD trial results, indicating market concerns over the drug's commercial viability.
- Trial Results Disappointment: Although Zenas characterized the INDIGO trial results as 'positive,' analysts noted that the drug's efficacy fell short of the necessary threshold for commercial success, leading to diminished investor confidence.
- CEO Acknowledgment of Disappointment: During a conference call on January 6, 2026, Zenas's CEO admitted that the hazard ratio did not meet expectations, causing the stock to fall another $1.41, or 8.49%, further heightening concerns about the company's future.
- Legal Investigation Launched: Pomerantz LLP is investigating whether Zenas and its executives engaged in securities fraud or other unlawful business practices, which could significantly impact the company's future legal liabilities and financial health.
Continue Reading
Zenas BioPharma Under Investigation as Stock Plummets 51.86%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Zenas BioPharma has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock declines.
- Clinical Trial Setback: On January 5, 2026, Zenas announced results from the INDIGO trial, which were termed “positive,” yet analysts noted that the drug's efficacy fell short of the commercial viability threshold, potentially impacting future sales prospects.
- Stock Price Volatility: Following the trial results, Zenas's stock plummeted by 51.86% in one day, from $34.50 to $16.61, reflecting strong market concerns regarding the company's future outlook.
- CEO Acknowledges Disappointment: During a conference call on January 6, 2026, Zenas's CEO expressed disappointment that the hazard ratio did not meet expectations, leading to an additional 8.49% drop in stock price, closing at $15.20.
Continue Reading